Literature DB >> 23462188

Chimerism patterns of long-term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-term stable mixed chimerism patients.

Arwen Stikvoort1, Jens Gertow, Mikael Sundin, Mats Remberger, Jonas Mattsson, Michael Uhlin.   

Abstract

Long-term stable mixed chimerism (MC) is a rare phenomenon after hematopoietic stem cell transplantation (HSCT) characterized by 5% to 95% residual recipient hematopoietic cells. The underlying mechanisms of MC are largely unknown. In this study we compared full donor chimerism with long-lasting stable MC for a median of 9.5 years (range, 5 to 16.5) post-HSCT in patients with nonmalignant diseases. Several factors significantly associated with the likelihood of stable MC development were identified by univariate analysis, eg, younger donor age, sibling donor, and conditioning regimen. Despite a limited patient cohort, our multivariate analysis could confirm that a sibling donor was associated with stable MC development. Furthermore, development of acute-graft-versus-host disease and blood stream infection was significantly more prevalent in the full donor chimerism patient group. Additionally, significant fluctuations in the recipient-to-donor chimerism ratio decreased over time after HSCT in MC patients.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23462188     DOI: 10.1016/j.bbmt.2013.02.015

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

1.  Excellent outcome with a high proportion of mixed chimerism in patients with severe aplastic anemia treated with partially T-cell-depleted peripheral hematopoietic stem cell transplants.

Authors:  S Masouridi-Levrat; F Simonetta; Y Beauverd; O Tsopra; Y Tirefort; C Stephan; E Levrat; M Ansari; F Verholen; E Roosnek; J R Passweg; Y Chalandon
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

Review 2.  A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review.

Authors:  Mohammad Vaezi; Maryam Souri; Seyed Amin Setarehdan; Amir Ali Hamidieh; Mohammad Reza Fazlollahi; Zahra Pourpak; Mohsen Badalzadeh; Shaghayegh Tajik; Seyed Alireza Mahdaviani; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Ann Hematol       Date:  2022-01-08       Impact factor: 3.673

3.  Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.

Authors:  Xiaowen Tang; Gheath Alatrash; Jing Ning; Haroon Jakher; Patricia Stafford; Madhushree Zope; Elizabeth J Shpall; Roy B Jones; Richard E Champlin; Peter F Thall; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-13       Impact factor: 5.742

4.  Influence of Mixed Chimerism on Outcome in Children With Anaemia After Haematopoietic Stem Cell Transplantation.

Authors:  Monika Lejman; Joanna Zawitkowska; Agnieszka Zaucha-Prażmo; Magdalena Cienkusz; Aleksandra Mroczkowska; Jerzy Kowalczyk; Katarzyna Drabko
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

5.  HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide.

Authors:  Kanwaldeep K Mallhi; Meera A Srikanthan; Kelsey K Baker; Haydar A Frangoul; Troy R Torgerson; Aleksandra Petrovic; Amy E Geddis; Paul A Carpenter; K Scott Baker; Brenda M Sandmaier; Monica S Thakar; Suzanne Skoda-Smith; Hans-Peter Kiem; Rainer Storb; Ann E Woolfrey; Lauri M Burroughs
Journal:  Biol Blood Marrow Transplant       Date:  2020-03-28       Impact factor: 5.742

6.  Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?

Authors:  Arwen Stikvoort; Mikael Sundin; Mehmet Uzunel; Jens Gertow; Berit Sundberg; Marie Schaffer; Jonas Mattsson; Michael Uhlin
Journal:  PLoS One       Date:  2016-05-06       Impact factor: 3.240

7.  Targeted busulfan and fludarabine-based conditioning for bone marrow transplantation in chronic granulomatous disease.

Authors:  Hee Young Ju; Hyoung Jin Kang; Che Ry Hong; Ji Won Lee; Hyery Kim; Sang Hoon Song; Kyung-Sang Yu; In-Jin Jang; June Dong Park; Kyung Duk Park; Hee Young Shin; Joong-Gon Kim; Hyo Seop Ahn
Journal:  Korean J Pediatr       Date:  2016-11-30

8.  Stem cell transplantation during cancer.

Authors:  Xiao-Ying Zhang; Pei-Ying Zhang
Journal:  Oncol Lett       Date:  2016-10-13       Impact factor: 2.967

9.  Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies.

Authors:  Emmanuel Levrat; Eddy Roosnek; Stavroula Masouridi; Bilal Mohty; Marc Ansari; Jean Villard; Jakob R Passweg; Yves Chalandon
Journal:  Bone Marrow Res       Date:  2015-11-10

10.  Y-chromosome DNA is present in the blood of female dogs suggesting the presence of fetal microchimerism.

Authors:  Sandra M Axiak-Bechtel; Senthil R Kumar; Sarah A Hansen; Jeffrey N Bryan
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.